Efficacy and prognostic factors of febuxostat therapy for chronic kidney disease complicated with hyperuricemia
Objective:To investigate the efficacy and prognostic factors of febuxostat therapy for chronic kidney disease (CKD) with hyperuricemia (HUA).Methods:In this prospective study, a total of 152 patients diagnosed with CKD complicated with HUA and treated from July 2019 to July 2020 were selected as the research subjects, and divided into either an observation group (treated with febuxostat, n=101) or a control group (treated with bicarbonate) by quota sampling. Sodium treatment, n=51). The therapeutic efficacy, serum uric acid (SUA), serum creatinine (Scr), blood urea nitrogen (BUN), 24 h urinary protein, glomerular filtration rate (eGFR), adverse reactions, and the percentage of patients with SUA not reaching the standard were compared between the two groups. According to whether the SUA reached the standard, the patients in the observation group were divided into a good prognosis subgroup (SUA＜360 μmol/L, n=77) and a poor prognosis subgroup (SUA≥360 μmol/L, n=24), and binary Logistic regression analysis was performed to identify the risk factors affecting the prognosis.Results:The total effective rate in the observation group was higher than that of the control group (P＜0.05). After treatment, SUA, Scr, BUN, and 24 h urine protein were significantly lower, and eGFR was significantly higher in the observation group than in the control group (P＜0.05). There was no significant difference between the good prognosis subgroup and the poor prognosis subgroup in gender, age, underlying disease, history of diabetes, and history of coronary heart disease (P＞0.05), but basal 24 h urinary protein, eGFR, Scr, SUA, and BUN differed significantly between the two subgroups (P＜0.05). Binary logistic regression analysis showed that CKD stage 5, history of gout, increased basal 24 h urinary protein, Scr, and SUA, and decreased eGFR were independent risk factors affecting the prognosis of patients in the observation group (P＜0.05).Conclusion:The efficacy of febuxostat in the treatment of CKD complicated with HUA is satisfactory, but CKD stage 5, history of gout, increased basal 24 h urinary protein, Scr, and SUA, and decreased eGFR affect the prognosis of patients.
万方数据
